Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Novelos Therapeutics
About
Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based
- 11 - 50
Details
- Last Funding Type
- Convertable Note
- Last Funding Money Raised
- $365K
- Industries
- Biotechnology,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 1996
- Number Of Employee
- 11 - 50
- Operating Status
- Close
Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company's compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company's second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 26, 2010 | Convertable Note | $365K | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advantage Capital
|
— | Convertable Note |
